← Back to Clinical Trials
Recruiting NCT04160429

NCT04160429 Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04160429
Status Recruiting
Phase
Sponsor City of Hope Medical Center
Condition Chronic Disease
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2018-11-09
Primary Completion 2029-07-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Biospecimen CollectionMedical Chart ReviewQuestionnaire Administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2018-11-09 with a primary completion date of 2029-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This trial collects and analyzes sweat and saliva samples compared to blood in detecting chemical concentrations in the body in patients with chronic or infectious diseases receiving medications. Wearable sweat sensors are capable of monitoring electrolytes and metabolites (sodium, potassium, glucose, lactate, etc.) for health monitoring and disease diagnosis. Designing wearable sweat sensors capable of providing information regarding drug administration may be challenging due to ultralow concentrations in biofluids. This trial seeks to determine if the use of a smart wristband can accurately measure the levels of chemicals and substances in sweat.

Eligibility Criteria

Inclusion Criteria: * Scheduled to receive medications including, but not limited to, cyclophosphamide, mycophenolic acid, mycophenolate mofetil, metformin or busulfan (any dose, any number of doses, any dosing frequency) as part of treatment at any time. Patients with chronic or infectious diseases can participate * Willingness to: * Provide blood, sweat, and saliva samples * Permit medical record review Exclusion Criteria: * Pilocarpine allergy * Difficulty with understanding written English

Contact & Investigator

Principal Investigator

Jeannine S McCune

PRINCIPAL INVESTIGATOR

City of Hope Medical Center

Frequently Asked Questions

Who can join the NCT04160429 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04160429 currently recruiting?

Yes, NCT04160429 is actively recruiting participants. Visit ClinicalTrials.gov or contact City of Hope Medical Center to inquire about joining.

Where is the NCT04160429 trial being conducted?

This trial is being conducted at Duarte, United States.

Who is sponsoring the NCT04160429 clinical trial?

NCT04160429 is sponsored by City of Hope Medical Center. The principal investigator is Jeannine S McCune at City of Hope Medical Center. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology